secwatch.observer — SEC 8-K summary
======================================

Issuer:     ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK:        0001281895
Form:       8-K
Filed at:   2024-05-06T23:59:59+00:00
Accession:  0001140361-24-024574
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rocket Pharma Q1 net loss $62.1M; cash $330.3M; EMA accepted MAA for FA, PDUFA date June 30 for LAD-I
--------------------------------------------------------------------------------

- Net loss of $62.1M ($0.66/sh) vs $58.3M ($0.73/sh) in Q1 2023; G&A rose to $22.1M on commercial prep.
- Cash and investments $330.3M as of March 31, 2024; expected operational runway into 2026.
- EMA accepted MAA for RP-L102 (Fanconi Anemia); BLA submission to FDA expected H1 2024.
- PDUFA date for KRESLADI (severe LAD-I) set for June 30, 2024; commercial preparations underway.
- Appointed Aaron Ondrey as CFO and Meg Dodge as VP of Investor Relations & Corporate Communications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1281895/000114036124024574/0001140361-24-024574-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1281895/000114036124024574/ef20028575_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-024574

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer